Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells

Lymphodepleting preconditioning is generally required prior to adoptive T cell therapy (ACT). Here the authors show in a preclinical melanoma model that anti-CD4 treatment as a post-conditioning regimen enhances the anti-tumor efficacy of ACT by promoting the expansion of IL-18Rαhi CD8+ T cells.

Guardado en:

Detalles Bibliográficos
Autores principales:	Seon-Hee Kim, Eunjung Cho, Yu I. Kim, Chungyong Han, Beom K. Choi, Byoung S. Kwon
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/9147d37f906c45f8af5f6a7e0c3e7b98
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9147d37f906c45f8af5f6a7e0c3e7b98
record_format	dspace
spelling	oai:doaj.org-article:9147d37f906c45f8af5f6a7e0c3e7b982021-12-02T17:19:40ZAdoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells10.1038/s41467-021-25559-72041-1723https://doaj.org/article/9147d37f906c45f8af5f6a7e0c3e7b982021-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25559-7https://doaj.org/toc/2041-1723Lymphodepleting preconditioning is generally required prior to adoptive T cell therapy (ACT). Here the authors show in a preclinical melanoma model that anti-CD4 treatment as a post-conditioning regimen enhances the anti-tumor efficacy of ACT by promoting the expansion of IL-18Rαhi CD8+ T cells.Seon-Hee KimEunjung ChoYu I. KimChungyong HanBeom K. ChoiByoung S. KwonNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Seon-Hee Kim Eunjung Cho Yu I. Kim Chungyong Han Beom K. Choi Byoung S. Kwon Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells
description	Lymphodepleting preconditioning is generally required prior to adoptive T cell therapy (ACT). Here the authors show in a preclinical melanoma model that anti-CD4 treatment as a post-conditioning regimen enhances the anti-tumor efficacy of ACT by promoting the expansion of IL-18Rαhi CD8+ T cells.
format	article
author	Seon-Hee Kim Eunjung Cho Yu I. Kim Chungyong Han Beom K. Choi Byoung S. Kwon
author_facet	Seon-Hee Kim Eunjung Cho Yu I. Kim Chungyong Han Beom K. Choi Byoung S. Kwon
author_sort	Seon-Hee Kim
title	Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells
title_short	Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells
title_full	Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells
title_fullStr	Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells
title_full_unstemmed	Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells
title_sort	adoptive immunotherapy with transient anti-cd4 treatment enhances anti-tumor response by increasing il-18rαhi cd8+ t cells
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9147d37f906c45f8af5f6a7e0c3e7b98
work_keys_str_mv	AT seonheekim adoptiveimmunotherapywithtransientanticd4treatmentenhancesantitumorresponsebyincreasingil18rahicd8tcells AT eunjungcho adoptiveimmunotherapywithtransientanticd4treatmentenhancesantitumorresponsebyincreasingil18rahicd8tcells AT yuikim adoptiveimmunotherapywithtransientanticd4treatmentenhancesantitumorresponsebyincreasingil18rahicd8tcells AT chungyonghan adoptiveimmunotherapywithtransientanticd4treatmentenhancesantitumorresponsebyincreasingil18rahicd8tcells AT beomkchoi adoptiveimmunotherapywithtransientanticd4treatmentenhancesantitumorresponsebyincreasingil18rahicd8tcells AT byoungskwon adoptiveimmunotherapywithtransientanticd4treatmentenhancesantitumorresponsebyincreasingil18rahicd8tcells
_version_	1718381038464401408

Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells

Ejemplares similares